가축용 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Livestock Vaccines Market was valued at USD 6.4 billion in 2024 and is estimated to grow at a CAGR of 7.1% to reach USD 12.6 billion by 2034, driven by increased awareness of animal health, the expansion of industrial farming, and advancements in vaccine technology. This rising trend is largely attributed to the heightened focus on disease prevention among farmers and a growing understanding of the economic advantages linked to immunization. As livestock farming becomes more industrialized, the need for comprehensive disease management strategies grows stronger. Technological innovation has further enabled the development of highly effective vaccines, strengthening animal health outcomes and improving productivity across farms. The emergence of frequent disease outbreaks globally has led to increased urgency around preventive measures, especially for poultry, which remains a highly vulnerable category. Global food security is increasingly reliant on livestock productivity, making animal health a critical aspect of agricultural sustainability. Moreover, the reduction in losses due to illness and mortality directly supports the economic viability of farming operations, especially in high-density production settings. The market continues to benefit from favorable government policies, industry collaborations, and increased investments in animal healthcare infrastructure.

Livestock animals such as cattle, swine, poultry, aquaculture species, and sheep and goats are central to the agricultural economy, serving various purposes including food production, fiber, and labor. Vaccination is widely recognized as an essential tool for safeguarding animal health and reducing the economic impact of infectious diseases. In 2024, the poultry segment held the largest market share, generating USD 2.4 billion in revenue, and is projected to reach USD 4.5 billion by 2034, growing at a CAGR of 6.5%. Poultry remains a global dietary staple, largely due to its lower production costs and faster turnover compared to other livestock. Increased demand for poultry products, particularly in rapidly developing regions, has accelerated the adoption of mass vaccination practices. The industry faces ongoing threats from viral and bacterial outbreaks, which have emphasized the importance of robust vaccination programs.

Among vaccine types, attenuated live vaccines dominate the market, holding a 45.9% share in 2024. This segment is expected to maintain its leading position through 2034 with a CAGR of 6.7%. These vaccines are highly effective because they mimic natural infections, providing strong and long-lasting immunity with fewer doses. Their use is common in addressing serious livestock diseases, making them a preferred solution for large-scale animal health management. These vaccines are also known for providing quicker immune responses, an essential factor in intensive farming setups where disease can spread rapidly.

Regarding administration routes, the oral segment is gaining significant traction due to its convenience and effectiveness in large-scale operations. Valued at USD 7.1 billion by 2034, this segment is projected to grow at a CAGR of 6.8%. Oral vaccines offer a stress-free way to immunize animals, especially in poultry, swine, and cattle sectors. Their ability to be administered through feed or water reduces handling, thereby minimizing injury risks and ensuring higher compliance across herds. Technological progress in vaccine formulation has improved the stability and efficiency of oral vaccines, making them increasingly suitable for widespread use.

In terms of applications, viral infection vaccines hold a substantial share of the market, anticipated to reach USD 6.8 billion by 2034, with a CAGR of 7.2%. Recurring viral outbreaks continue to pose major challenges to the livestock industry, both in terms of animal health and economic impact. These diseases significantly reduce production yields, compelling farmers to adopt effective preventive solutions. The ongoing investment in research and development by vaccine manufacturers is expected to drive innovation in this segment, improving the efficacy and accessibility of viral vaccines.

When it comes to distribution, veterinary hospital pharmacies accounted for the largest revenue share of USD 3.3 billion in 2024 and are forecasted to hit USD 6.4 billion by 2034, growing at a CAGR of 6.9%. These facilities are preferred for their comprehensive care offerings, including diagnostics, consultations, and immediate vaccine administration. The expansion of veterinary care networks, especially in emerging markets, is contributing to better access to animal healthcare. The structured delivery system in veterinary hospitals ensures timely vaccination, reducing missed opportunities and increasing overall effectiveness.

The United States leads the North American livestock vaccines market, achieving a valuation of USD 2.4 billion in 2024. This leadership is supported by an advanced animal healthcare framework, high veterinary expenditure, and consistent government support for preventive livestock care. Disease prevalence continues to drive demand for vaccination, pushing the market forward.

Key players such as Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco, and Ceva collectively hold around 45% of the global market. Their dominance is attributed to broad product lines, strong global distribution networks, and strategic investments in next-generation vaccine development. The livestock vaccines industry remains moderately consolidated, with these leaders setting the pace for innovation, efficiency, and sustainability in animal health solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of livestock diseases
    • 3.2.1.2 Growing awareness among farmers about the benefits of vaccination.
    • 3.2.1.3 Government initiatives and policies supporting animal health and food security.
    • 3.2.1.4 Technological advancements leading to the development of more effective vaccines
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with vaccine development and distribution
    • 3.2.2.2 Regulatory hurdles that can delay product approvals and market entry.
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Poultry
• 5.3 Cattle
• 5.4 Swine
• 5.5 Aquaculture
• 5.6 Sheep and goats

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Attenuated live vaccine
• 6.3 Conjugate vaccine
• 6.4 Inactivated vaccine
• 6.5 Recombinant vaccine
• 6.6 Other vaccine types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parentral
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Bacterial infections
• 8.3 Viral infections
• 8.4 Parasitic infections
• 8.5 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Veterinary hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Biogenesis Bago
• 11.2 Bioveta
• 11.3 Boehringer Ingelheim
• 11.4 Ceva
• 11.5 Elanco
• 11.6 HIPRA
• 11.7 Indian Immunologicals
• 11.8 Merck Animal Health
• 11.9 Neogen
• 11.10 Phibro Animal Health
• 11.11 SAN VET
• 11.12 Vaxxinova
• 11.13 Venkys
• 11.14 Virbac
• 11.15 Zoetis